PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
|Articles|February 1, 2016
- Pharmaceutical Technology-02-02-2016
- Volume 40
- Issue 2
Vacuum De-aeration Apparatus
The Vacuum De-aeration Apparatus from Copley Scientific is used in semisolid pharmaceutical testing for de-gassing the medium used in vertical diffusion cells (VDCs) to measure the drug release profile of semisolid products.
The Vacuum De-aeration Apparatus from Copley Scientific is used in semisolid pharmaceutical testing for de-gassing the medium used in vertical diffusion cells (VDCs) to measure the drug release profile of semisolid products. The apparatus is designed to provide a source of prewarmed, de-gassed media for use in VDCs.
It operates by heating the receptor media up to 45 °C under vacuum conditions of 90 kPa below atmospheric pressure. Performance data suggest that dissolved oxygen can typically be reduced to below 4 ppm within one hour.
www.copleyscientific.com
Articles in this issue
over 10 years ago
Preventing Film Coating Problems by Designover 10 years ago
Going Small to Achieve Commercial-Scale Successover 10 years ago
Innovating for Innovationover 10 years ago
Faster, Cheaper, and Greenerover 10 years ago
Macro Mattersover 10 years ago
Innovative Therapies Require Modern Manufacturing Systemsover 10 years ago
Creating Robust CAPA Systemsover 10 years ago
Measurement Uncertainty without the Mathover 10 years ago
Pharmaceutical Technology, February 2016 Issue (PDF)over 10 years ago
Crossflow Filtration System for Process DevelopmentRelated to this article
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Karthik Iyer, Eli Lilly, details an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS
global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.
At PDA/FDA Joint Regulatory Conference 2026, PCI Pharma's Bassler details how a QMS overhaul turned an FDA 483 into stronger quality culture.
Trending on Pharmaceutical Technology
1
Driving Quality Culture to Manage Risk: Lessons from an FDA Inspection Response
2
FDA's IND Pilot Puts CMC Review First
3
Mature Medicines Divestment Signals Shift in Manufacturing Strategy
4
Spray Drying Capacity Signals Faster Paths for Poorly Soluble Drugs
5